

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Sillekens et al.

Application No.: 10/559,949

International Filing Date: March 8, 2004

For: ***NUCLEIC ACID SEQUENCES THAT CAN BE USED AS PRIMERS AND PROBES IN THE AMPLIFICATION AND DETECTION OF SARS CORONAVIRUS***

December 22, 2006

MAIL STOP PCT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

**REQUEST TO CORRECT INVENTORSHIP
UNDER 37 C.F.R. § 1.497(d)**

Sir:

Pursuant to 37 C.F.R. § 1.497(d), it is requested that **Marlieke Overdijk**, residing at Looisehoeve 14 5708 TK HELMOND, The Netherlands, and **Saskia van de Laar**, residing at Newtonplein 47, 5283 JH BOXTEL, The Netherlands, be **added** as inventors on the above-identified application. In support of this request are included:


- (a) A statement by Marlieke Overdijk and a statement by Saskia van de Laar, respectively, the inventors to be added, that the error in inventorship in the international application occurred without deceptive intention on their part;
- (c) A Consent of Assignee duly executed by a representative of bioMerieux, B.V., the assignee of the above-identified application, agreeing to the change of inventorship; and
- (d) A check for \$260.00 (\$130.00 as the processing fee pursuant to 37 C.F.R. §1.17(i) and (\$130.00 as fee for the surcharge pursuant to 37 C.F.R. § 1.493(h)).

The original errors in designating the inventorship of the above-identified application were inadvertent made without deceptive intent. Therefore, it is respectfully requested that the inventors listed above be added and to this application.

Applicants are submitting these documents with a Declaration and Power of Attorney document signed by inventors **P.T.G. Sillekens, Marlieke Overdijk and Saskia van de Laar.**

The enclosed amount of \$260.00 is believed to be correct. However, the Commissioner is authorized to charge any additional fees due in connection with this paper or credit any overpayment to Deposit Account No. 50-0220.

Respectfully submitted,



Mary L. Miller
Registration No. 39,303

USPTO Customer No. 20792
Myers Bigel Sibley & Sajovec, P.A.
Post Office Box 37428
Raleigh, North Carolina 27627
Telephone: (919) 854-1400
Facsimile: (919) 854-1401


CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR §1.10

"Express Mail" mailing label number: EV769238071US

Date of Deposit: December 22, 2006

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Tracy Wallace



Attorney Docket No. 9310-151

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Sillekens et al..

Application No.: 10/559,949

International Filing Date: March 8, 2004

For: ***NUCLEIC ACID SEQUENCES THAT CAN BE USED AS PRIMERS AND PROBES IN THE AMPLIFICATION AND DETECTION OF SARS CORONAVIRUS***

MAIL STOP PCT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

**CONSENT OF ASSIGNEE FOR
CORRECTION OF INVENTORSHIP PURSUANT TO 37 C.F.R. §1.48(a)**

Sir:

The corporation of BioMerieux B.V. , the assignee of the above-identified application, hereby consents to the amendment of the application under 37 C.F.R. § 1.48(a) to add Marlieke Overdijk and Saskia van de Laar as inventors on the above-referenced patent application. Accordingly, the correct inventors on the above-mentioned application are **P.T.G. Sillekens, Marlieke Overdijk and Saskia van de Laar.**

Respectfully submitted
on behalf of BioMerieux B.V.,

Signature:  _____

Name: Laurent CAUCA

Title: Patent attorney

Date: April 13, 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Sillekens et al.

Application No.: 10/559,949

International Filing Date: March 8, 2004

For: *NUCLEIC ACID SEQUENCES THAT CAN BE USED AS PRIMERS AND PROBES IN THE AMPLIFICATION AND DETECTION OF SARS CORONAVIRUS*

COMMISSIONER FOR PATENTS


P.O. BOX 1450

ALEXANDRIA, VA 22313

**STATEMENT IN SUPPORT OF REQUEST
FOR CORRECTION OF INVENTORSHIP UNDER 37 C.F.R. § 1.48(a)(2)**

I, **Saskia van de Laar**, do hereby declare and state as follows:

1. I was not originally named as an inventor on the above-identified patent application, but I should have been. This omission was inadvertent and occurred without any deceptive intent on my part.
2. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.



Saskia van de Laar

Date

april 11, 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Sillekens et al.

Application No.: 10/559,949

International Filing Date: March 8, 2004

For: *NUCLEIC ACID SEQUENCES THAT CAN BE USED AS PRIMERS AND PROBES IN THE AMPLIFICATION AND DETECTION OF SARS CORONAVIRUS*

COMMISSIONER FOR PATENTS

P.O. BOX 1450

ALEXANDRIA, VA 22313

**STATEMENT IN SUPPORT OF REQUEST
FOR CORRECTION OF INVENTORSHIP UNDER 37 C.F.R. § 1.48(a)(2)**

I, **Marlieke Overdijk**, do hereby declare and state as follows:

1. I was not originally named as an inventor on the above-identified patent application, but I should have been. This omission was inadvertent and occurred without any deceptive intent on my part.
2. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.



Marlieke Overdijk

11-04-2006

Date